|
Jul 25
|
Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia
|
|
Jul 25
|
Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029
|
|
Jul 24
|
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
|
|
Jul 24
|
Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion
|
|
Jul 24
|
Here's Why Novartis (NVS) is a Strong Value Stock
|
|
Jul 24
|
Arvinas, Inc. (ARVN): A Bull Case Theory
|
|
Jul 24
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Jul 24
|
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
|
|
Jul 24
|
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
|
|
Jul 24
|
Behcet's Disease Market Research Report 2025-2035 | Key Trends, Regulatory Framework, Epidemiology, Clinical Trial Analysis, Market Dynamics
|
|
Jul 24
|
Tinnitus Market Analysis and Forecast Report 2025-2035 | Pharma Giants Drive Treatment Advances with Off-Label CNS Drugs Amid Intensifying Market Competition
|
|
Jul 24
|
Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care
|
|
Jul 24
|
CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva
|
|
Jul 24
|
Novartis' (VTX:NOVN) Performance Is Even Better Than Its Earnings Suggest
|
|
Jul 23
|
Rheumatoid Arthritis Therapeutics Market Forecast Report 2025-2034 | Rising Preference for Combination Therapies, and Entry of Generic Drugs Supports Expansion
|
|
Jul 23
|
Epilepsy Drugs Market Growth Analysis, Forecast Trends and Outlook Report 2025-2034 | Demand for Generic Epilepsy Drugs Rises as Patent Expirations Fuel Market Growth
|
|
Jul 22
|
Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for Rare Diseases
|
|
Jul 22
|
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
|
|
Jul 22
|
Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving [UPDATED]
|
|
Jul 22
|
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
|